On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive…
Read more…
In a First, FDA Grants Full Approval to Anti-Amyloid Drug for Alzheimer’s
